What Frazier Life Sciences Management, L.P. reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1892134 · Filed Nov 16, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 19M |
| +5.0% |
| $461.8M |
| 11.5% |
ERASErasca, Inc. | 29.5M | +18.0% | $432.1M | 10.7% |
MBXMBX Biosciences, Inc. | 6.7M | ±0% | $389.9M | 9.7% |
ARQTArcutis Biotherapeutics, Inc. | 9.9M | ±0% | $261M | 6.5% |
MAZEMaze Therapeutics, Inc. | 5.3M | +5.0% | $143.6M | 3.6% |
TRVITrevi Therapeutics, Inc. | 9.5M | −4.0% | $136.6M | 3.4% |
KRYSKrystal Biotech, Inc. | 391.3K | −18.7% | $130.1M | 3.2% |
PVLAPalvella Therapeutics, Inc. | 882.4K | ±0% | $121.7M | 3% |
ATTOAttovia Therapeutics, Inc. | 7M | New | $120.8M | 3% |
BRVEBraveheart Bio, Inc. | 5.3M | New | $106.4M | 2.6% |
PHATPhathom Pharmaceuticals, Inc. | 12.5M | ±0% | $91M | 2.3% |
PBLSParabilis Medicines, Inc. | 2.3M | +21.3% | $75.3M | 1.9% |
DYNDyne Therapeutics, Inc. | 3.9M | +22.2% | $62.1M | 1.5% |
ACHVAchieve Life Sciences, Inc. | 7.6M | ±0% | $61.6M | 1.5% |
MNKDMannkind Corp | 15.8M | +138.7% | $61.4M | 1.5% |
IRONDisc Medicine, Inc. | 934.9K | −31.0% | $61.2M | 1.5% |
TARSTarsus Pharmaceuticals, Inc. | 720.3K | −1.1% | $56.6M | 1.4% |
VORVor Biopharma Inc. | 2.7M | +7.9% | $52.4M | 1.3% |
ASNDAscendis Pharma A/S | 225.2K | New | $51.3M | 1.3% |
ZLABZai Lab Ltd | 1.9M | ±0% | $50.1M | 1.2% |
ACRSAclaris Therapeutics, Inc. | 8.7M | +77.2% | $45.9M | 1.1% |
AURAAura Biosciences, Inc. | 7.1M | ±0% | $44.6M | 1.1% |
ALLOAllogene Therapeutics, Inc. | 22.4M | ±0% | $35.9M | 0.9% |
BCRXBiocryst Pharmaceuticals Inc | 4M | ±0% | $33.4M | 0.8% |
CLDXCelldex Therapeutics, Inc. | 900.1K | New | $29.2M | 0.7% |
ACADAcadia Pharmaceuticals Inc | 1.4M | ±0% | $29M | 0.7% |
STTKShattuck Labs, Inc. | 3.8M | ±0% | $25.6M | 0.6% |
IMCRImmunocore Holdings plc | 829.8K | +71.2% | $25.1M | 0.6% |
DSGNDesign Therapeutics, Inc. | 1.8M | ±0% | $22.7M | 0.6% |
EOLSEvolus, Inc. | 2.6M | ±0% | $21M | 0.5% |
SRPTSarepta Therapeutics, Inc. | 1.1M | New | $19.5M | 0.5% |
RLAYRelay Therapeutics, Inc. | 1M | ±0% | $18.3M | 0.5% |
LXEOLexeo Therapeutics, Inc. | 4.8M | ±0% | $16.3M | 0.4% |
VALNValneva SE | 2.3M | ±0% | $14.2M | 0.4% |
KLRAKailera Therapeutics, Inc. | 1.2M | +9.1% | $13.7M | 0.3% |
GLUEMonte Rosa Therapeutics, Inc. | 1M | ±0% | $11.9M | 0.3% |
ORICOric Pharmaceuticals, Inc. | 751.7K | New | $10.1M | 0.3% |
AUTLAutolus Therapeutics plc | 4.4M | ±0% | $8.6M | 0.2% |
NAMSWNewAmsterdam Pharma Co N.V. | 500.3K | ±0% | $6.3M | 0.2% |
SVRASavara Inc | 1.1M | −88.5% | $5.7M | 0.1% |
XLOXilio Therapeutics, Inc. | 422.5K | ±0% | $3.8M | 0.1% |
TCGXTCGX Acquisition Corp. | 300K | New | $3.8M | 0.1% |
IBIOiBio, Inc. | 2M | ±0% | $2.3M | 0.1% |